It appears to the Securities and Exchange Commission (the “Commission”) that the public interest and the protection of investors require a suspension in the trading of the securities of Parallax Health Sciences, Inc. (“Parallax” or “the Company”) (CIK No. 1388410) because of questions regarding the accuracy and adequacy of information in the marketplace. Those questions relate to statements Parallax made about its purported development of a rapid screening test for COVID-19 and its purported access to large quantities of COVID-19 diagnostic testing kits and personal protective equipment. The statements were made on the company’s website and in press releases issued by the Company on March 12, March 16, March 17, March 23 and March 24, 2020.

Parallax is a Nevada corporation with its principal place of business in Santa Monica, California. The Company’s common stock is quoted on OTC Link (previously Pink Sheets), operated by OTC Markets Group Inc., under the symbol PRLX. As of April 8, 2020, Parallax’s stock had nine market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT on April 13, 2020, through 11:59 p.m. EDT on April 24, 2020.

By the Commission.

Vanessa A. Countryman
Secretary